Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × lopinavir-ritonavir drug combination × Clear all

NCT04455958 2021-04-26

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms